Top

International Journal of Clinical Oncology

Published in:

01-10-2019 | Computed Tomography | Original Article

Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer

Authors: Ayumi Shikama, Takeo Minaguchi, Wataru Takao, Yoshihiko Hosokawa, Keiko Nishida, Nobutaka Tasaka, Azusa Akiyama, Manabu Sakurai, Hiroyuki Ochi, Toyomi Satoh

Published in: International Journal of Clinical Oncology | Issue 10/2019

Abstract

Objective

The selection criteria for secondary cytoreductive surgery (SCS) for recurrent endometrial cancer (EC) remain to be defined. The present study aimed to identify predictors for favorable survival after SCS for the disease.

Methods

We retrospectively reviewed the medical records of 112 patients who relapsed by 2016 among 1052 who were diagnosed with primary EC between 1985 and 2014. Characteristics associated with overall survival (OS) after SCS were identified using univariate and multivariate analyses.

Results

Twenty-nine of the 112 patients who relapsed underwent SCS. Complete resection was achieved in 18 (62%) patients, whose OS after SCS was significantly better than that of patients receiving incomplete resection (68 vs. 20 months; p = 0.001). Endometrioid histology and performance status (PS) 0 were significant and independent factors for a favorable OS (p = 0.005, and 0.049). The OS of patients with both factors was better than patients with one or no factors (median 75, 19 and 4 months; p = 0.001 and 0.00001). The number of predictors was associated with the rate of complete resection (p = 0.001).

Conclusions

Patients with endometrioid histology and PS 0 should be offered SCS for recurrent EC. Prospective trials are warranted to verify this proposal.

Available only for authorised users

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRef

Fung-Kee-Fung M, Dodge J, Elit L et al (2006) Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 101(3):520–529CrossRefPubMed

Morris M, Alvarez RD, Kinney WK et al (1996) Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 60(2):288–291CrossRefPubMed

Barakat RR, Goldman NA, Patel DA et al (1999) Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 75(1):99–102CrossRefPubMed

Scarabelli C, Campagnutta E, Giorda G et al (1998) Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol Oncol 70(1):90–93CrossRefPubMed

Campagnutta E, Giorda G, Piero GD et al (2004) Surgical treatment of recurrent endometrial carcinoma. Cancer 100(1):89–96CrossRefPubMed

Bristow RE, Santillan A, Zahurak ML et al (2006) Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol 103(1):281–287CrossRefPubMed

Awtrey CS, Cadungog MG, Leitao MM et al (2006) Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 102(3):480–488CrossRefPubMed

Ren Y, Shan B, Shi D et al (2014) Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study. BMC Cancer 14(1):135CrossRefPubMedPubMedCentral

10.

Papadia A, Bellati F, Ditto A et al (2015) Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Ann Surg Oncol 22(13):4204–4210CrossRefPubMed

11.

Turan T, Tasci T, Karalok A et al (2015) Salvage cytoreductive surgery for recurrent endometrial cancer. Int J Gynecol Cancer 25(9):1623–1632CrossRefPubMed

12.

Bricou A, Bendifallah S, Daix-Moreux M et al (2018) A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN Study Group. Int J Gynecol Cancer 28(7):1278–1284CrossRefPubMed

13.

Iwase H, Furukawa S, Hirasawa T et al (2018) The clinical features of recurrent endometrial cancer in Japan: chemotherapy instead of radiotherapy as postoperative adjuvant treatment. Int J Gynecol Cancer 28(8):1616–1623CrossRefPubMed

14.

Barlin JN, Puri I, Bristow RE (2010) Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 118(1):14–18CrossRefPubMed

15.

Gottwald L, Pluta P, Piekarski J et al (2010) Long-term survival of endometrioid endometrial cancer patients. Arch Med sci 6(6):937–944CrossRefPubMedPubMedCentral

16.

Odagiri T, Watari H, Hosaka M et al (2011) Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol 22(1):3–8CrossRefPubMedPubMedCentral

17.

Zang RY, Li ZT, Tang J et al (2004) Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100(6):1152–1161CrossRefPubMed

18.

Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539–543CrossRefPubMed

19.

Minaguchi T, Satoh T, Matsumoto K et al (2016) Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers. Int J Clin Oncol 21(3):573–579CrossRefPubMed

20.

Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295CrossRefPubMed

Title: Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer
Authors: Ayumi Shikama
Takeo Minaguchi
Wataru Takao
Yoshihiko Hosokawa
Keiko Nishida
Nobutaka Tasaka
Azusa Akiyama
Manabu Sakurai
Hiroyuki Ochi
Toyomi Satoh
Publication date: 01-10-2019
Publisher: Springer Singapore
Keywords: Computed Tomography
Computed Tomography
Endometrial Cancer
Endometrial Cancer
Published in: International Journal of Clinical Oncology / Issue 10/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01469-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2019

Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma

Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study

Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

Clinical significance of the pattern-based classification in endocervical adenocarcinoma, usual and variants

Frequency and predictors of detecting early locoregional recurrence/disease progression of oral squamous cell carcinoma with high-risk factors on imaging tests before postoperative adjuvant radiotherapy

A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types

Keynote webinar | Spotlight on antibody–drug conjugates in cancer